Moreover, the anti-obesity drug liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, can alleviate airway inflammation by suppressing NLRP3 inflammasome activity (Hur et al., 2021). This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.